Konecny, Gottfried E <br/><br/>
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.  [electronic resource] 

 -  The Lancet. Oncology  Jun 2015 
 - 686-94 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(15)70159-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Benzimidazoles--administration & dosage<br/>Disease-Free Survival<br/>Endometrial Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Mutation<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Quinolones--administration & dosage<br/>Receptor, Fibroblast Growth Factor, Type 2--genetics<br/>Treatment Outcome